FDA approves Novo Nordisk's Alhemo for hemophilia A and B without inhibitors, following strong Phase 3 results showing reduced bleeding episodes.

Hympavzi, made by Pfizer, is the first antitissue-factor pathway inhibitor to be approved for the blood-clotting disorder, as well as the first hemophilia drug to offer a once-weekly treatment ...

Replacing clotting factors forms the basis of hemophilia treatment, but people with hemophilia can also benefit from working with physical therapists, mental health professionals, dietitians, and ...

The trial infuses SPK-8011, a new recombinant AAV vector engineered to express factor VIII in human liver cells, in 18 men with hemophilia A and demonstrates a 91.5% decrease in bleeding episodes.

In contrast, hemophilia A is caused by the lack or insufficiency of clotting factor 8. [2] It is 3 to 4 times more common than hemophilia B and is also less severe. [1] ...

Everyone experiences nosebleeds at some point, but nosebleeds with no known cause can be a sign of hemophilia, according to the American Academy of Pediatrics (AAP). This can happen when a blood ...

"Multiyear Factor VIII Expression After AAV Gene Transfer for Hemophilia A," New England Journal of Medicine, November 18, 2021, DOI: 10.1056/NEJMoa2104205 ...

A decline in annualized rates of factor VIII use of 98.6% and treated bleeding of 83.8% (P <.001 for both comparisons) A median factor VIII activity level of 5 IU/dL or higher in 88.1% of participants ...

The most common form of hemophilia is hemophilia A, which arises from a deficiency in clotting factor VIII. Around 1 in every 5,000 to 10,000 males is born with this condition.

"Patients who develop antibodies to the coagulation factors usually prescribed for hemophilia have a complicated treatment," said study leader Paris Margaritis, DPhil, a hematology researcher in ...

Grifols is working to enhance the lives of the roughly 100,000 people around the world who have hemophilia but receive little or no treatment. The company is halfway into an eight-year initiative ...

SINCE the discovery of hemophilia B (PTC deficiency, congenital factor IX deficiency, Christmas disease) in 1952, 1–3 many attempts have heen made to prepare practical and effective concentrates ...